Business
Why Moderna Is Less Risky Than You Think
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Biotech investing is not for the weak-hearted. While the clinical and regulatory success of a drug can mean huge gains, any failure in the development and commercialization process can literally decimate a biotech investor’s portfolio.
Many investors consider Moderna (NASDAQ: MRNA) to be one such risky biotechnology company, with fortunes largely dependent on the success or failure of its experimental COVID-19 vaccine, mRNA-1273. But although Moderna may be riskier than other prominent COVID-19 vaccine players such as Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN), that doesn’t mean it’s purely a speculative play….
-
Noosa News21 hours agoBrisbane council budget 2025: Winners and losers
-
Business16 hours ago3 of the best ASX stocks to buy now with $2,500
-
Noosa News16 hours agoRapist who tortured woman for weeks claims he deserves a lighter sentence for not letting her die
-
General10 hours agoSeeking a reset on the environment debate, Murray Watt gathers business and conservation groups in search of a deal